HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gerhild Angyalosi Selected Research

Tobramycin (Nebcin)

1/2021Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study.
10/2019Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).
1/2019Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.
11/2016Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
4/2016One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
3/2014Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
8/2013Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
3/2011Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
1/2011Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
4/2010Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gerhild Angyalosi Research Topics

Disease

11Cystic Fibrosis (Mucoviscidosis)
10/2019 - 12/2009
7Infections
10/2019 - 12/2009
3Pseudomonas Infections
09/2012 - 04/2010
2Bronchiectasis
01/2021 - 10/2019
2Cough
03/2011 - 01/2011
1Ototoxicity
03/2011
1Dust Mite Allergy
11/2002
1Human Influenza (Influenza)
02/2002

Drug/Important Bio-Agent (IBA)

11Tobramycin (Nebcin)FDA LinkGeneric
01/2021 - 12/2009
8PowdersIBA
01/2021 - 01/2011
5SolutionsIBA
01/2019 - 04/2010
4Anti-Bacterial Agents (Antibiotics)IBA
01/2019 - 04/2010
3Pharmaceutical PreparationsIBA
03/2014 - 12/2009
1AminoglycosidesIBA
12/2009
1AllergensIBA
11/2002
1Dermatophagoides pteronyssinus antigen p 1IBA
11/2002
1EpitopesIBA
02/2002
1Hemagglutinins (Hemagglutinin)IBA
02/2002

Therapy/Procedure

2Therapeutics
04/2010 - 12/2009